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S U M M A R Y
Infection due to the Middle East respiratory syndrome coronavirus (MERS-CoV) is widespread. The
present study was performed to assess the protocols used for the molecular diagnosis of MERS-CoV by
analyzing the nucleotide sequences of viruses detected between 2012 and 2015, including sequences
from the large outbreak in eastern Asia in 2015. Although the diagnostic protocols were established only
2 years ago, mismatches between the sequences of primers/probes and viruses were found for several of
the assays. Such mismatches could lead to a lower sensitivity of the assay, thereby leading to false-
negative diagnosis. A slight modiﬁcation in the primer design is suggested. Protocols for the molecular
diagnosis of viral infections should be reviewed regularly after they are established, particularly for
viruses that pose a great threat to public health such as MERS-CoV.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Middle East respiratory syndrome coronavirus (MERS-CoV) is an
enveloped virus with a positive-sense RNA genome. Infection with
the virus causes severe respiratory symptoms in humans, with a case
fatality rate as high as 37%.1 Camels may be a source of infection to
humans.2 Human-to-human transmission is also possible, but this
requires close contact, such as health care-related contact without
proper measures for infection control and prevention.3 The earliest
case of MERS was reported in Jordan, and MERS-CoV was
subsequently isolated from cases in Saudi Arabia only a short time
later.4 Since then, infections have been endemic mainly in the
Middle East. However, MERS-CoV has spread sporadically to other
areas, including Europe, North America, Africa, and Southeast and
East Asia, by travelers from the Middle East.5
The laboratory diagnosis of MERS-CoV infection is mainly
performed using real-time reverse transcription PCR (RT-PCR) to
detect viral RNA in specimens. Interim recommendations from the
World Health Organization (WHO) in 2015 for the laboratory
testing of MERS-CoV included protocols for RT-PCR that were
developed by the University Hospital Bonn and the US Centers for* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Disease Control and Prevention.6–9 This document included seven
assays: (1) the UpE assay, which is considered highly sensitive and
is recommended for screening,7 (2) the ORF1a assay, which is
considered equally as sensitive as the UpE assay,6 (3) the ORF1b
assay, which is considered less sensitive than the ORF1a assay,6,7
and the (4) N2 and (5) N3 assays, which can complement UpE and
ORF1a assays for screening and conﬁrmation.8,9 To date, these
assays have shown no cross-reactivity with other human
coronaviruses.6–8 Sequencing protocols for further conﬁrmation,
namely the (6) RdRpSeq and (7) NSeq assays, were also developed.6
Because MERS-CoV is an RNA virus that can evolve rapidly,
there remains concern that these protocols may not be suitable for
the detection of current MERS-CoV because of a mismatch among
sequences in the primer/probe regions. This study was performed
to analyze recent viral genomic nucleic acid sequences and to
discuss the efﬁcacy of the RT-PCR protocols for the molecular
diagnosis of MERS-CoV infections.
2. Methods
As of July 29, 2015, sequence data for 386 MERS-CoV were
available at ‘Virus Variation’ (http://www.ncbi.nlm.nih.gov/
genome/viruses/variation; GenBank accession numbers of the
sequence data analyzed are available upon request). The dataciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Conservation of the primer and probe region sequences of the WHO-recommended assays for the molecular diagnosis of MERS-CoV
Assay Regions Sequence (50 to 30)a Conservationb
UpE Forward primer G ‘C’ AACGCGCGATTCAGTT 99% (115/116)
Reverse primer GCCTCTACACGGGACCCATA 100% (115/115)
Probe C ‘T’ CTTCACATAATCGCCCCGAGCTCG 99% (115/116)
ORF1a Forward primer CCACTACTCCCATTTCGTCAG 100% (119/119)
Reverse primer CAGTATGTGTAGTGCGCATATAAGCA 100% (119/119)
Probe TTGCAAATTGGCTTGCCCCCACT 100% (119/119)
ORF1b Forward primer TTCGATGTTGAGGGTGCTCAT 100% (116/116)
Reverse primer TCACACCAGTTGAAAATCCTAATTG 100% (115/115)
Probe CCCGTAATGCATGTGGCACCAATGT 100% (116/116)
N2 Forward primer GGCACTGAGGACCCACGTT 100% (127/127)
Reverse primer TTG ‘C’ GACATACCCATAAAAGCA 99% (126/127)
Probe CCCCAAATTGCTGAGCTTGCTCCTACA 100% (126/126)
N3 Forward primer GGGTGTACCTCTTAAT ‘G’ CCAATTC 95% (125/131)
Reverse primer TCT ‘G’ TCCTGTCTCCGCCAAT 99% (130/131)
Probe ACCCC ‘T’ GCGCAAAATGCTGGG 92% (120/131)
RdRpSeq Forward primer TGCTATWAGTGCTAAGAATAGRGC 100% (119/119)
Reverse primer GCATWGCNCW ‘G’ TCACACTTAGG 0% (0/110)
‘Corrected reverse primer’ GCATWGCNCWATCACACTTAGG 100% (120/120)
Reverse-nested primer CACTTAGGRTARTCCCAWCCCA 100% (120/120)
NSeq Forward primer CCTTCGGTACAGTGGAGCCA 100% (127/127)
Reverse primer GATGGG ‘G’ TT ‘G’ CCAAACACAAAC 49% (53/108)
‘Modiﬁed reverse primer’ GATGGGRTTRCCAAACACAAAC 99% (107/108)
Forward-nested primer TGACCCAAAGAATCCCAACTAC 100% (128/128)
WHO, World Health Organization; MERS-CoV, Middle East respiratory syndrome coronavirus.
a The position of the mismatched nucleotide is indicated with quotation marks.
b In parenthesis: number of sequences perfectly matched/number of sequences available for the region.
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sequences from the big outbreak in eastern Asia in 2015.1 Data for
these 386 sequences, including complete as well as partial genome
sequences, were obtained and analyzed. Sequence data were
aligned with ClustalW to assess genetic changes in the nucleotide
sequences of the primer and probe regions of the assays described
above. The numbers of viral sequences that matched the primer/
probe sequences perfectly were counted.
3. Results and discussion
As mentioned in the Introduction above, the UpE, ORF1a, N2,
and N3 assays can be used for screening because of their high
sensitivity.6–9 Among these, only the primer and probe designs of
the ORF1a assay showed 100% conservation of all sequence data
available today (Table 1). Minor mismatches were found for the
UpE assay (one nucleotide substitution in two sequences) and N2
assay (one nucleotide substitution in one sequence), and signiﬁ-
cant mismatches were found for the N3 assay. The primer/probe
regions were found to be well conserved, except for the N3 assay. In
addition, mismatches were not found in the 30 end region of
primers for the UpE and N2 assays (Table 1). The sensitivity of the
assays may not be greatly affected. No mismatches were found for
the ORF1b assay.
With regard to the sequencing assays, no sequence data that
matched the sequence of the reverse primer for the RdRpSeq assay
was found. However, a single common mismatch in all sequence
data was found. When the mismatched nucleotide was corrected,
the RdRpSeq assay matched all the sequence data perfectly
(‘corrected reverse primer’, Table 1). In addition, viral sequences of
the reverse primer region for the NSeq assay were not highly
conserved; the sequence matched only 49% of strains. Based on
these results, the use of a modiﬁed reverse primer for the assay is
suggested, in order to reduce the possibility of a mismatch
(‘modiﬁed reverse primer’, Table 1).
Several mismatches among viral sequences in the primer/probe
regions for molecular diagnosis were identiﬁed in this study. Such
mismatches could lead to a lower sensitivity of the assay, thereby
leading to false-negative diagnosis. The mismatched sequence datacould have been generated by errors in PCR or sequencing during
viral nucleotide sequence analysis because of the incorporation of
the wrong nucleotide.10 However, it is more likely that the RNA
virus has evolved and that this has accidentally resulted in the
induction of mutation/s in the region targeted by the primer/probe
for RT-PCR, only 2 years after the establishment of the protocols.
Fortunately, no or few mismatches were found for most of the
MERS-CoV screening assays. Nevertheless, protocols for the
molecular diagnosis of viral infections should be reviewed
regularly after they are established, particularly for viruses that
pose a great threat to public health such as MERS-CoV.
Acknowledgement
This research was supported by the Japan Initiative for Global
Research Network on Infectious Diseases (J-GRID) from the Japan
Agency for Medical Research and Development, AMED. The
funding source had no involvement in the study design, in the
collection, analysis, and interpretation of the data, in the writing of
the manuscript, or in the decision to submit the manuscript for
publication.
Conﬂict of interest: All authors declare no conﬂicts of interest.
References
1. World Health Organization. Middle East respiratory syndrome coronavirus
(MERS-CoV). Republic of Korea: WHO; 2015.
2. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM,
Madani TA. Evidence for camel-to-human transmission of MERS coronavirus. N
Engl J Med 2014;370:2499–505.
3. Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, et al; First cases
of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in
France, investigations and implications for the prevention of human-to-human
transmission, France, May 2013. Euro Surveill 2013;18(24), pii: 20502.
4. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation
of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med
2012;367:1814–20.
5. World Health Organization Regional Ofﬁce for Europe. Middle East respiratory
syndrome coronavirus (MERS-CoV): situation update and cases reported in the
Netherlands. WHO; 2014.
6. Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for
laboratory conﬁrmation of novel human coronavirus (hCoV-EMC) infections.
Euro Surveill 2012;17(49). pii: 20334.
Y. Furuse et al. / International Journal of Infectious Diseases 40 (2015) 25–27 277. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al.
Detection of a novel human coronavirus by real-time reverse-transcription
polymerase chain reaction. Euro Surveill 2012;17(39). pii: 20285.
8. Lu X, Whitaker B, Sakthivel SK, Kamili S, Rose LE, Lowe L, et al. Real-time reverse
transcription-PCR assay panel for Middle East respiratory syndrome coronavirus.
J Clin Microbiol 2014;52:67–75.9. World Health Organization. Laboratory testing for Middle East respiratory
syndrome coronavirus—interim guidance (revised). WHO; 2015.
10. Keohavong P, Thilly WG. Fidelity of DNA polymerases in DNA ampliﬁcation.
Proc Natl Acad Sci U S A 1989;86:9253–7.
